Silence Therapeutics has appointed Michael Khan as its new chief medical adviser. He will also serve on the company's board of directors.
Khan is an associate professor of medicine at the University of Warwick.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Nature this week: weighting scheme increases GWAS power, and more.
Marc Tessier-Lavigne is to be the next president of Stanford University.
Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.
Journals and research funding agencies pledge to enable the sharing of Zika virus research.